Download PDF
Thromb Haemost 1995; 74(01): 025-035
DOI: 10.1055/s-0038-1642648
Special Colloquium
Schattauer GmbH Stuttgart

The Fibrinolytic System: from Petri Dishes to Genetic Engineering

Marc Verstraete
Center for Molecular and Vascular Biology, University of Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Publication Date:
09 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Denys J, De Marbaix H. Les peptonisations provoquees par le chlorofoime. Cellule 1889; 5: 197-197
    PubMedGoogle Scholar
  • 2 Dastre A. Fibrinolyse dans le sang. Arch Norm Pathol 1893; 5: 661-661
    PubMedGoogle Scholar
  • 3 Nolf P. Contribution a Fetude de la coagulation du sang V. La fibrinolyse. Arch Int Physiol 1908; 6: 306-359
    PubMedGoogle Scholar
  • 4 Yudin SS. Transfusion of cadaver blood. JAMA 1936; 106: 997-999
    CrossrefPubMedGoogle Scholar
  • 5 Fleisher MS, Loeb L. On tissue fibrinolysis. J Biol Chem 1915; 21: 477-501
    PubMedGoogle Scholar
  • 6 Astrup T. Fibrinolysis in the organism. Blood 1956; 11: 781-806
    PubMedGoogle Scholar
  • 7 Tillett WS, Gamer RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933; 56: 485-502
    PubMedGoogle Scholar
  • 8 Tillett WS, Gamer RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933; 58: 485-502
    CrossrefPubMedGoogle Scholar
  • 9 Milstone H. A factor in normal human blood which participates in streptococcal fibrinolysis. J Immunol 1941; 42: 109-116
    PubMedGoogle Scholar
  • 10 Tagnon HJ, Davidson CS, Taylor FHL. The coagulation defect in hemophilia: a comparison of the proteolytic activity of chloroform preparations of hemophilic and normal plasma. J Clin Invest 1943; 22: 127-134
    CrossrefPubMedGoogle Scholar
  • 11 Christensen LR. Streptococcal fibrinolysis: A proteolytic reaction due to a serum enzyme activated by streptococcal fibrinolysis. J Gen Physiol 1945; 28: 263-383
    PubMedGoogle Scholar
  • 12 MacFarlane RG, Biggs R. Fibrinolysis: its mechanism and significance. Blood 1948; 3: 1167-1187
    PubMedGoogle Scholar
  • 13 Wun TC, Schleuning WD, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem 1982; 257: 3276-3283
    PubMedGoogle Scholar
  • 14 Lassen M. Heat denaturation of plasminogen in the fibrin plate method. Acta Physiol Scandinav 1952; 27: 371-376
    PubMedGoogle Scholar
  • 15 Claeson G, Aurell L, Friberger P, Gustavsson S, Karlson G. Designing of peptide substrates. Different approaches amplified by new chromogenic substrates for kallikrein and urokinase. Haemostasis 1978; 7: 62-68
    PubMedGoogle Scholar
  • 16 Christensen LR. Protamine purification of streptokinase and effect of pH and temperature on reversible inactivation. J Gen Physiol 1947; 30: 465-473
    CrossrefPubMedGoogle Scholar
  • 17 Tillett WS, Sherry S. The effect in patients of streptococcal fibrinolysin (streptokinase) and streptoccocal deoxyribonuclease on fibrinous, purulent, and sanguineous pleural exudations. J din Invest 1949; 28: 173-190
    PubMedGoogle Scholar
  • 19 Johnson AJ, Tillett WS. Lysis in rabbits of intravascular blood clots by the streptococcal fibrinolytic system (streptokinase). J Exp Med 1952; 95: 449-464
    CrossrefPubMedGoogle Scholar
  • 20 Cliffton EE, Cannamela DA, Grossi C. In vivo studies of human plasmin. Intravenous injection in dogs and rabbits. J Appl Physiol 6: 143-150 1953;
    CrossrefPubMedGoogle Scholar
  • 21 Johnson AJ, McCarty WR. The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase. J din Invest 1959; 38: 1627-1643
    PubMedGoogle Scholar
  • 22 Guest MM, Celander DR. Urokinase: Physiologic activatorof profibrinolysis. Tex Rep Biol Med 1961; 19: 89-105
    PubMedGoogle Scholar
  • 23 White WF, Barlow GH, Mozen MM. The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 1966; 5: 2160-2169
    CrossrefPubMedGoogle Scholar
  • 24 Barlow GH. Urinary and kidney cell plasminogen activator (urokinase). In: Lorand L. ed. Methods in Enzymology Vol.45. San Diego; CA: Academic Press: 1976: 239-244
    Google Scholar
  • 25 Harpel PC, Chang TS, Verderber E. Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. J Biol Chem 1985; 260: 4432-4440
    PubMedGoogle Scholar
  • 26 Rakoczi I, Wiman B, Collen D. On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin. Biochim Biophys Acta 1978; 540: 295-300
    CrossrefPubMedGoogle Scholar
  • 27 Fletcher AP, Alkjaersig N, Sherry S, Genton E, Hirsh J, Bachmann F. Development of urokinase as a thrombolytic agent: maintenance of a sustained thrombolytic state in man by its intravenous infusion. J Lab Clin Med 1965; 654: 713-731
    PubMedGoogle Scholar
  • 28 Gross R, Haiti W, Kloss G, Rahn B. Thrombolyse durch Infusionen hochgereinigter Streptokinase. Erfahrungen und Untersuchungen an den ersten 50 Kranken. Dtsch Med Wschr 1960; 85: 2129-2135
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Verstraete M, Amery A, Veimylen J. Feasibility of adequate thrombolytic therapy with streptokinase in peripheral arterial occlusion. Brit Med J 1963; 1: 1499-1504
    CrossrefPubMedGoogle Scholar
  • 30 Schmutzler R, Koller F. Thrombolytic treatment of acute peripheral and venous occlusions. Angiologica 1968; 5: 119-128
    PubMedGoogle Scholar
  • 31 Fletcher AP, Alkjaersig M, Sherry S. The clearance of heterologous protein from the circulation of normal and immunized man. J din Invest 1958; 37: 1306-1315
    PubMedGoogle Scholar
  • 32 Amery A, Maes H, Veimylen J, Verstraete M. The streptokinase reactivity test. I Standardization. Thromb Diath Haemorrh 1963; 9: 175-188
    PubMedGoogle Scholar
  • 33 Verstraete M, Amery A, Veimylen J. The feasibility of adequate thrombolytic therapy with streptokinase in peripheral arterial occlusions. Thromb Diathes Haemonh 1962; 7: 211-236
    PubMedGoogle Scholar
  • 34 Verstraete M, Tytgat G, Amery A, Veimylen J. Thrombolytic therapy with streptokinase using a standard dosage. Thromb Diath Haemorrh 1966; 16: 494-500
    PubMedGoogle Scholar
  • 35 Urokinase Pulmonary Embolism Trial Study Group:. Urokinase pulmonary embolism trial: phase I results. J Am Med Ass 1970; 214: 2163-2172
    CrossrefPubMedGoogle Scholar
  • 36 Urokinase-Streptokinase Pulmonary Embolism Trial Study Group:. Phase II results:. a national cooperative trial. JAMA 1974; 229: 1606-1613
    CrossrefPubMedGoogle Scholar
  • 37 Poliwoda H, Schroder R, Heckner F. Erste Erfahrungen mit der fibrinolytisehen Therapie beim Akuten Myocardinfarct. Dtsch Med Wschr 1963; 88: 218-224
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Amery A, Roeber G, Vermeulen HJ, Verstraete M. Single-blind randomised multicentre trial comparing heparin and streptokinase treatment in recent myocardial infarction. Acta Med Scand Suppl 1969; 505: 5-35
    PubMedGoogle Scholar
  • 39 European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction:. Streptokinase in acute myocardial infarction. N Engl J Med 1979; 301: 797-797
    CrossrefPubMedGoogle Scholar
  • 40 Verstraete M, Van de Loo J, Jesdinsky HJ. Streptokinase in acute myocardial infarction. Acta Med Scand Suppl 198;. 648: 7117-7117
    PubMedGoogle Scholar
  • 41 DeWood MA, Spores J, Notske R, Lowell T, Mouser T, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902
    CrossrefPubMedGoogle Scholar
  • 42 Rijken DC, Wijngaards G, Zaal-De JongM, Welbergen J. Purification and partial characterization of plasminogen activatorfrom human uterine tissue. Biochim Biophys Acta 1979; 580: 140-153
    CrossrefPubMedGoogle Scholar
  • 43 Wilson EL, Becker ML B, Hoal EG, Dowdle EB. Molecular species of plasminogen activators secreted by normal and neoplastic human cells. Cancer Res 1980; 40: 933-938
    PubMedGoogle Scholar
  • 44 Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 156: 7035-7041
    PubMedGoogle Scholar
  • 45 Weimar W, Stibbe J, van Seyen AJ, Billiau A, DeSomer P, Collen D. Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator. Lancet 1981; 2: 1018-1020
    PubMedGoogle Scholar
  • 46 Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KAA, de Geest H, Verstraete M, Collen D, Sobel B. Clot-selective coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. NEngl J Med 1984; 310: 609-613
    CrossrefPubMedGoogle Scholar
  • 47 Opdenakker G, Weening H, Collen D, Billiau A, DeSomer P. Messenger RNA for human tissue plasminogen activator. Eur J Biochem 1982; 121: 269-274
    CrossrefPubMedGoogle Scholar
  • 48 Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in£. coli. Nature 1983; 201: 214-221
    PubMedGoogle Scholar
  • 49 Collen D, Stassen JM, Marafino Jr BJ, Builder S, DeCock F, Ogez J, Tajiri D, Pennica D, Bennett WF, Salwa J, Hoyng CF. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. J Pharm Exp Ther 1984; 231: 146-152
    PubMedGoogle Scholar
  • 50 Bergmann SR, Fox KA A, Ter-Pogossian MM, Sobel BE, Collen D. Clotselective coronary thrombolysis with tissue-type plasminogen activator Science. 1983; 220: 1181-1183
    PubMedGoogle Scholar
  • 51 Van de Werf F, Bergmann SR, Fox KAA, DeGeest H, Hoyng CF, Sobel BE, Collen D. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation 1984; 69: 605-610
    CrossrefPubMedGoogle Scholar
  • 52 Gold HK, Fallon JT, Yasuda T, Khaw BA, Newell JB, Leinbach RC, Guerrero JL, Vislosky FM, Hoyng CF, Grossbard E, Collen D. Coronary thrombolysis with recombinant human tissue-type plasminogen activator. Circulation 1984; 70: 700-707
    CrossrefPubMedGoogle Scholar
  • 53 Flameng W, VandeWerf F, Vanhaecke J, Verstraete M, Collen D. Coronary thrombolysis and infarct size reduction following intravenous infusion of recombinant tissue-type plasminogen activator in non-human primates. J Clin Invest 1985; 75: 84-90
    CrossrefPubMedGoogle Scholar
  • 54 Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, Leinbach RC, Brinker JA, Ludbrook PA, Yasudat BulkleyB H, Robison AK, Hutter AM, Bell WR, Sparado JJ, Khaw BA, Grossbard EB. Coronary thrombolysis with recombinant human tissue-type plasminogen activator A prospective, randomized, placebo-controlled trial. Circulation 1984; 70: 1012-1017
    CrossrefPubMedGoogle Scholar
  • 55 Pietrolungo JF, Topol EJ. Thrombolytic therapy for acute myocardial infarction in thrombolytic therapy for peripheral vascular disease AJ Comerota, editor J.B. Lippincott Company; Philadelphia: 1995: 349-398
    Google Scholar
  • 56 Bernik MB, Oiler EP. Plasminogen activator and proactivator (urokinase precursor) in lung cultures. J Am Med Assoc 1976; 31: 465-472
    PubMedGoogle Scholar
  • 57 Nolli ML, Sarubbi E, Corti A, Rabbiati F, Soffientini A, Blasi F, Parenti F, Cassani G. Production and characterization of human recombinant single chain urokinase-type plasminogen activator from mouse cells. Fibrinolysis 1989; 3: 101-106
    PubMedGoogle Scholar
  • 58 Holmes WE, Pennica D, Blaber M, Rey MW, Guenzler WA, Steffens G, Heyneker HL. Cloning and expression of the gene for pro-urokmase in Escherichia coli. Biotechnology 1985; 3: 923-929
    CrossrefPubMedGoogle Scholar
  • 59 Eaton DL, Scott RW, Baker JB. Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease nexin. J Biol Chem 1984; 259: 6241-6247
    PubMedGoogle Scholar
  • 60 Nielsen LS, Hansen JG, Skriver L, Wilson EL, Kaltoft K, Zeuthen J, Dano K. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinty chromatography with monoclonal antibody. Biochemistry 1982; 24: 6410-6415
    PubMedGoogle Scholar
  • 61 Steffens GJ, Guenzler WA, Oetting F, Frankus E, Flohe L. The complete amino acid sequence of low molecular mass urokinase from human urine Hoppe-Seyler’s Z Physiol Chem. 1982; 363: 1043-1058
    PubMedGoogle Scholar
  • 62 Gurewich V, Pannell R, Lowe S. Effective and fibrin-specific clot lysis by a zymogen precursor forni of urokinase (pro-urokinase)- a study in vitro and in two animal species. J Clin Invest 1984; 73: 1731-1734
    CrossrefPubMedGoogle Scholar
  • 63 Pannell R, Gurewich V. The activation of plasminogen by single chain urokinase or by two-chain urokinase - a demonstration that single chain urokinase has a low catalytic activity (prourokinase). Blood 1987; 69: 22-26
    PubMedGoogle Scholar
  • 64 Collen D, De Cock F, Lijnen HR. Biological and thrombolytic properties of proenzyme and active forms ofhuman urokinase. II. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys. Thromb Haemost 1984; 52: 24-26
    PubMedGoogle Scholar
  • 65 Stump DC, Lijnen HR, Collen D. Purification and characterization of single-chain urokinase-type plasminogen activatorfrom human cell cultures. J Biol Chem 1986; 261: 1274-1278
    PubMedGoogle Scholar
  • 66 Gruppo Italiano per lo Studio della Streptochinasi nelT Infarcto Miocardico (GISSI-2):. A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71
    PubMedGoogle Scholar
  • 67 The International Study Group:. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71-79
    CrossrefPubMedGoogle Scholar
  • 68 ISIS-3 (Third International Study of Infarct Survival) Collaborative Group:. A randomized trial of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-777
    CrossrefPubMedGoogle Scholar
  • 69 Sobel BE, Collen D. Questions unresolved by the third International Study of infarct survival. Am J Cardiol 1992; 70: 385-389
    CrossrefPubMedGoogle Scholar
  • 70 Neuhaus KL, von Essen R, Tebbe U, Vogt A, Roth M, Riess M, Niederer W, Forycki F, Wirtzfeld A, Maeurer W, Limbourg P, Merx W, Haerten K. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplate results of the rt-PA-APSAC patency study (TAPS). J Am CoE Cardiol 1992; 19: 885-891
    PubMedGoogle Scholar
  • 71 Grines CL, Nissen SE, Booth DC, Gurley JC, CheUiah N, Wolf R, Blankenship J, Branco MC, Bennett K, DeMaria AN. the Kentucky Acute Myocardial Infarction Trial (KAMIT) Group: A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Circulation 1991; 84: 540-549
    CrossrefPubMedGoogle Scholar
  • 72 deBono DP, Simoons ML, Tijssen J, Arnold AER, Betriu A, Burgersdijk C, Lopez BescosL, MueUer E, Pfisterer M, Vande WerfF, Zylstra F, Verstraete M. for the European Cooperative Study Group: Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group. Br Hear J 1992; 67: 122-128
    CrossrefPubMedGoogle Scholar
  • 73 The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682
    CrossrefPubMed
  • 74 The GUSTO Angiographic Investigators:. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622
    CrossrefPubMedGoogle Scholar
  • 75 Andreotti F, Kluft C, Hackett DR, Davies GJ, Maseri A. Thrombin generation after fast or prolonged regimens of tissue-type plasminogen activator. Lancet 1993; 342: 937-938
    PubMedGoogle Scholar
  • 76 Purvis JA, Trouton TG, Robert MJD, McKeown P, MulhoEand MG, DalzeE GWN, Wilson CM, Patterson GC, Webb SW, Khan MM, CampbeU NPS, Adgey J. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction. J Am CoE Cardiol 1994; 23: 6-10
    PubMedGoogle Scholar
  • 77 Lijnen HR, CoEen D. Strategies for the improvement of thrombolytic agents. Thromb Haemostas 1991; 66: 88-110
    PubMedGoogle Scholar
  • 78 Collen D, deBono DP, Lijnen HR, Pannekoek H. Development of novel thrombolytic agents. J Int Med 1994; 236: 433-437
    CrossrefPubMedGoogle Scholar
  • 79 Madison EL. Probing structure-function relationships of tissue-type plasminogen activator by site-specific mutagenesis. Fibrinolysis 1994’ 8: 221-236
    PubMedGoogle Scholar
  • 80 Kohnert U, Rudolph R, Verheijen JH, Weening-Verhoeff EJD, Stem A, Opitz U, Martin U, Lili H, Prinz H, Lechner M, Kresse GB, Buckel P. FischerS: Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Prot Engineer 1992; 5: 93-100
    CrossrefPubMedGoogle Scholar
  • 81 Sturzebecher J, Neumann U, Kohnert U, Kresse GB. FischerS: Mapping of the catalytic site of CHO-t-PA and the t-PA variant BM 06.022 by synthetic inhibitors and substrates. Prot Sc 1991; 1: 1007-1013
    PubMedGoogle Scholar
  • 82 Hajjar KA: The endothelial cell tissue plasminogen activator receptor. J Biol Chem 1991; 266: 21962-21970
    PubMed
  • 83 Martin U, Fischer S, Kohnert U, Opitz U, Rudolph R, Sponer G, Stem A, Strein K. Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. Thromb Haemostas 1991; 65: 560-564
    PubMedGoogle Scholar
  • 84 Martin U, van Mollendorf E, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. Clin Phaimacol Ther 1991; 50: 429-436
    PubMedGoogle Scholar
  • 85 Martin U, Kohler J, Sponer G, Strein K. Pharmacokinetics of the novel recombinant plasminogen activator BM 06.022 in rats, dogs, and nonhuman primates. Fibrinolysis 1992; 6: 39-43
    PubMedGoogle Scholar
  • 86 Muller M, Haerer W, Ellbriick D, Martin U, Konig R, Seifried E. for the GRECO Study Group: Pharmacokinetics and effects on the hemostatic system of bolus application of a novel recombinant plasminogen activator in AMI patients. Fibrinolysis 6. Suppl 02 26. Abstract 63 1992
    PubMedGoogle Scholar
  • 87 Martin U, Bader R, Bohm E, Kohnert U, van Mollendorf E, Fischer S, Sponer G. BM 06 022 a novel recombinant plasminogen activator. Cardiovasc Drag Rev 1993; 11: 299-311
    PubMed
  • 88 Neuhaus K-L, von Essen R, Vogt A, Tebbe U, Rustige J, Wagner HJ, Appel KF, Stienen V, Konig R, Meyer-Sabellek W. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German recombinant plasminogen activator study. J Am Coll Cardiol 1994; 24: 55-60
    CrossrefPubMedGoogle Scholar
  • 89 Tebbe U, von Essen R, Smolarz A, Limbourg P, Rox J, Rustige J, Vogt A, Wagner J, Meyer-Sabellek W, Neuhaus KL. Open, noncontrolled dosefinding study with a novel recombinant plasminogen activator(BM 06.022) given as a double bolus in patients with acute myocardial infarction. Am J Cardiol 1993; 72: 518-524
    CrossrefPubMedGoogle Scholar
  • 90 Smalling RW, Bode C, Kalbfleisch J, Sen P, Limbourg F, Forycki G, Habib G, Feldman R, Hohnloser S, Seals A. for the RAPID Investigators: Improvement of global and regional LV function by the bolus administration of recombinant plasminogen activator (r-PA) in acute myocardial infarction: a comparison with standard dose alteplase Circulation. 1994; 90: 562 (abstr 3029)
    PubMedGoogle Scholar
  • 91 Lijnen HR, Collen D. Development of chimeric tissue-type/urokinase-type plasminogen activators for thrombolytic therapy. Curr Opin Invest New Drugs 1993; 2: 495-504
    PubMedGoogle Scholar
  • 92 Collen D, Stassen JM, Demarsin E, Kieckens L, Lijnen HR, Nelles L. Pharmacokinetics and thrombolytic properties of chimaeric plasminogen activators consisting of the NH2-terminal region of human tissue-type plasminogen activator and the COOH-terminal region of human single chain urokinase-type plasminogen activator. J Vase Med Biol 1989; 1: 234-240
    PubMedGoogle Scholar
  • 93 Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. Circulation 1991; 84: 1216-1234
    CrossrefPubMedGoogle Scholar
  • 94 Vande WerfF, Lijnen HR, Collen D. Coronary thrombolysis withK1 K«P , a chimeric tissue-type and urokinase-type plasminogen activator. Afeasibility study in six patients with acute myocardial infarction. Coron Art Dis 1993 4: 929-933
    PubMedGoogle Scholar
  • 95 Gardell SJ, Duong LT, Diehl RE, Yoik JD, Hare TR, Register RB, Jacobs JW, Dixon RAF, Friedman PA. Isolation, characterizaton, and cDNA cloning of a vampire bat salivaiy plasminogen activator. J Biol Chem 1989 264: 17947-17952
    PubMedGoogle Scholar
  • 96 Bergum PW, Garden SJ. Vampire bat salivary plasminogen activator exhibits a strict and fastidious requirement for polymeric fibrin as its cofactor, unlike human tissue-type plasminogen activator. J Biol Chem 1992; 267: 17726-17731
    PubMedGoogle Scholar
  • 97 Kratzschmar J, Haendler B, Langer G, Boidol W, Bringmann P, Alagon A, Donner P, Schleuning WD. The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus: cloning and expression. Gene 1991; 105: 229-237
    CrossrefPubMedGoogle Scholar
  • 98 Garden SJ, Hare TR, Bergum PW, Cuca GC, O’NeiU-PaUadino L, Zavodny SM. Vampire bat salivary plasminogen activator is quiescent in human plasma in the absence of fibrin unlike human tissue plasminogen activator. Blood 1990; 76: 2560-2564
    PubMedGoogle Scholar
  • 99 GardeU SJ, Ramjit DR, Stabilito II, Fujita T, Lynch JJ, Cuca GC, Jain D, Wang S, Tung J, Mark GE, Shebuski RJ. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat saHvary plasminogen activator in rabbits. Circulation 1991; 84: 244-253
    CrossrefPubMedGoogle Scholar
  • 100 MeUott MJ, Stabilito II, Holahan MA. et al: Vampire bat salivaiy plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombolysis. Arterioscl Thromb 1992; 12: 212-221
    CrossrefPubMedGoogle Scholar
  • 101 Witt W, Baldus B, Bringmann P, Cashion L, Donner P, Schleuning WD. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats. Blood 1992; 79: 1213-1217
    PubMedGoogle Scholar
  • 102 Witt W, Maass B, Baldus B. et al. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. Circulation 1994; 90: 421-426
    CrossrefPubMedGoogle Scholar
  • 103 Collen D, Lijnen HR. Staphylokinase, afibrin-speciflcplasminogen activator with therapeutic potential. Blood 1994; 84: 680-686
    PubMedGoogle Scholar
  • 104 Lijnen HR, Van HoefB, Vandenbossche L, Collen D. Biochemical properties of natural and recombinant staphylokinase. Fibrinolysis 6: 214-225 1992;
    PubMedGoogle Scholar
  • 105 Collen D, Van HoefB, Schlott B, Hartmann M, Guhrs CH, Lijnen HR. Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase. EurJBiochem 1993; 216: 307-314
    PubMedGoogle Scholar
  • 106 Schlott B, Hartmann M, Guhrs KH, Birch-Hirschfeld E, Gase A, Vetteimann S, Collen D, Lijnen HR. Functional properties of recombinant staphylokinase variants obtained by site specific mutagenesis of methionine-26. Biochim Biophys Acta 1994; 1204: 235-242
    CrossrefPubMedGoogle Scholar
  • 107 Collen D, Van de WerfF. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 1993; 87: 1850-1853
    CrossrefPubMedGoogle Scholar
  • 108 Vanderschueren SMF, Stassen JM, Collen D. On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb Haemostas 1994; 72: 297-301
    PubMedGoogle Scholar